信达生物（01801）今日盘中大涨5.12%，股价表现强劲。这一涨势主要受到公司最新发布的2024年度业绩报告的推动。
根据信达生物公布的2024年度财报，公司实现营收约94.22亿元，同比增长51.8%。毛利约79.12亿元，同比增长56.1%。值得注意的是，公司年内亏损大幅收窄至9463.1万元，同比减少90.8%，显示出公司经营状况的显著改善。
信达生物表示，2024年财务业绩的大幅提升主要来自两个方面：一是高速的收入增长，包括强劲的产品收入增长势头和授权费收入的增加；二是运营效率的持续改善，包括产品生产成本的进一步优化，销售和营销活动效率和生产力及管理职能效率的进一步提升。这些因素共同推动了公司业绩的显著改善，也增强了投资者对公司未来发展的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.